Equities research analysts expect Penumbra Inc (NYSE:PEN) to post earnings per share of $0.11 for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Penumbra’s earnings. The lowest EPS estimate is $0.09 and the highest is $0.13. Penumbra posted earnings per share of $0.10 in the same quarter last year, which suggests a positive year-over-year growth rate of 10%. The business is scheduled to announce its next quarterly earnings results after the market closes on Tuesday, February 26th.
On average, analysts expect that Penumbra will report full-year earnings of $0.48 per share for the current fiscal year, with EPS estimates ranging from $0.47 to $0.48. For the next year, analysts expect that the company will post earnings of $0.76 per share, with EPS estimates ranging from $0.69 to $0.83. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Penumbra.
Several analysts recently issued reports on PEN shares. Canaccord Genuity upped their price objective on shares of Penumbra from $138.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, January 30th. Bank of America reaffirmed a “buy” rating and set a $36.00 price objective on shares of Penumbra in a research note on Monday, October 29th. BMO Capital Markets upped their price objective on shares of Penumbra from $150.00 to $152.00 and gave the company a “market perform” rating in a research note on Tuesday, November 6th. ValuEngine raised shares of Penumbra from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Zacks Investment Research raised shares of Penumbra from a “hold” rating to a “buy” rating and set a $153.00 price objective for the company in a research note on Tuesday, October 23rd. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Penumbra has an average rating of “Buy” and an average price target of $143.43.
In related news, Director Harpreet Grewal sold 666 shares of the company’s stock in a transaction dated Thursday, January 3rd. The shares were sold at an average price of $121.27, for a total transaction of $80,765.82. Following the completion of the sale, the director now owns 13,247 shares of the company’s stock, valued at approximately $1,606,463.69. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bridget O’rourke sold 1,200 shares of the business’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $142.19, for a total transaction of $170,628.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,952 shares of company stock valued at $399,839. 10.70% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. boosted its holdings in Penumbra by 30.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 437 shares of the company’s stock valued at $53,000 after purchasing an additional 103 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Penumbra by 10.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,028 shares of the company’s stock valued at $248,000 after purchasing an additional 185 shares during the last quarter. Xact Kapitalforvaltning AB boosted its holdings in Penumbra by 8.2% in the 4th quarter. Xact Kapitalforvaltning AB now owns 5,258 shares of the company’s stock valued at $643,000 after purchasing an additional 400 shares during the last quarter. Capital Investment Advisory Services LLC acquired a new position in Penumbra in the 4th quarter valued at about $56,000. Finally, Teachers Advisors LLC boosted its holdings in Penumbra by 2.1% in the 3rd quarter. Teachers Advisors LLC now owns 41,994 shares of the company’s stock valued at $6,287,000 after purchasing an additional 883 shares during the last quarter. Institutional investors own 72.22% of the company’s stock.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Recommended Story: Stock Split
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.